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Background: The issue of when to start treatment in Parkinson’s disease (PD) remains controversial. Some
favour treatment at diagnosis while others opt for a ‘‘wait and watch’’ policy. The effect of the latter policy on
the self reported health status of people with PD is unknown.
Aims: To record self reported health status through longitudinal use of a validated PD specific questionnaire
(PDQ-39) in untreated PD patients in multiple centres in the UK. To compare patients who were left untreated
with those who were offered treatment during follow-up.
Methods: A multicentre, prospective, ‘‘real life’’ observational audit based study addressing patient reported
outcomes in relation to self reported health status and other sociodemographic details.
Results: 198 untreated PD were assessed over a mean period of 18 months. During two follow-up
assessments, the self reported health status scores in all eight domains of the PDQ-39 and the overall PDQ-39
summary index worsened significantly (p,0.01) in patients left untreated. In a comparative group in whom
treatment was initiated at or soon after diagnosis, there was a trend towards improvement in self reported
health status scores after treatment was started.
Conclusions: This study addresses for the first time self reported health status, an indicator of health related
quality of life, in untreated PD. The findings may strengthen the call for re-evaluation of the policy to delay
treatment in newly diagnosed patients with PD.
D
rug treatment for Parkinson’s disease (PD), particularly
in its early stages, remains controversial, as highlighted in
a recent review.1 Most controlled trials of early drug
therapy in PD focus on dyskinesias and motor symptoms as end
points, while self reported health status and non-motor
symptoms such as depression, hallucinations, falls, sleep
problems, restless legs and dementia are not adequately
considered.2 Furthermore, the external validity of such trials
is questionable because of the exclusion, for instance, of elderly
patients and those with active comorbid medical problems.2 3
Patients diagnosed with early PD may not be treated initially on
the assumption that the condition is too mild to warrant
treatment. A ‘‘wait and watch’’ policy is thus undertaken and
drug therapy is initiated only when the disability becomes
apparent and ‘‘functional’’ impairment occurs.4 5 This policy is
dictated in part by the absence of disease modifying therapy.1
The argument for starting PD therapy at diagnosis would be
strengthened if an adverse effect on self reported health status
of delaying treatment was documented. This can be achieved by
using validated self reported health status measures, such as
the PD specific questionnaire, PDQ-39, which incorporates
aspects of motor and non-motor function in PD.2 6 Because of
controversy regarding whether such scores truly represent
quality of life or, more correctly, a patient centred overview of
physical, social and psychological health, we refer to the PDQ-
39 results as a health status rather than quality of life (which
some consider a personal issue which is unquantifiable).7
PDLIFE is a prospective multicentre UK based national audit
study examining the serial changes in self reported health
status of people with PD in the early untreated stage or on
monotherapy, using the PDQ-39. As part of this study, serial
self reported health status data and demographic details were
collected in PD patients who were not started on specific
therapy at the initial consultation and who were subsequently
followed for a mean of 18 months.
To our knowledge, this is the first report of a longitudinal
follow-up designed to address primarily self reported health
status measures in a cohort of unselected drug naı¨ve PD
patients who were clinically judged not to require pharmaco-
logical treatment.
PATIENTS AND METHODS
Methods
PDLIFE is an ongoing multicentre prospective audit based
study, established by a collaborative clinical group and
supported by the UK Parkinson’s Disease Society, to address
the serial changes in self reported health status measures in
response to therapeutic intervention in PD patients over a
5 year period. The initial phase (phase 1) of PDLIFE is complete
and includes 10 UK centres. Phase 1 was designed to replicate a
‘‘real life’’ situation as clinical trials of anti-PD drugs usually
concentrate on young patients with minimal comorbid illness
presenting to tertiary centres. For this reason, to avoid bias, the
Abbreviations: DNPD, drug naı¨ve patient with Parkinson’s disease; HY
stage, Hoehn and Yahr stage; MTPD, patient receiving monotherapy for
Parkinson’s disease; PD, Parkinson’s disease; PDQ, Parkinson’s Disease
Questionnaire; UPDRS, Unified Parkinson’s Disease Rating Scale
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centres included in the PDLIFE study ranged from tertiary
regional movement disorder clinics to specialised PD clinics for
the elderly and clinics in a district general hospital setting.
Patients
Patients fulfilling the UK Brain Bank criteria for PD were
potentially eligible.8 As the aim of the study was to address the
changes in self reported health status in untreated PD and the
effect of any anti-PD drug related intervention on self reported
health status, only untreated patients (drug naı¨ve, DNPD) or
those receiving monotherapy with any anti-PD agent (MTPD)
were included. The serial follow-up design also allowed
assessment of patients who were initially untreated at baseline
and thereafter were started on treatment. The combination of
levodopa and entacapone was included in the MTPD group.
Patients receiving anti-PD drug treatment for more than
5 years, patients in complex or palliative stages of PD and
those with an uncertain diagnosis were excluded.
All patients completed a standard audit form at the first visit
which noted age, sex, age at diagnosis, family history,
occupational history, social support, exposure to toxins,
ethnicity, history of head injury, olfactory disturbance, alcohol
consumption, comorbidities and a detailed drug history. In
addition, Hoehn and Yahr (HY) staging and subtype of
Parkinson’s disease (akinesia dominant, tremor dominant or
mixed) were recorded, and patients completed the PDQ-39
questionnaire.
PDQ-39
The PDQ-39 is the most used and validated disease specific
instrument for self reported health status in PD.6 7 The PDQ-39
has 39 questions and eight domains/dimensions, covering
mobility, activities of daily living, emotional well being, stigma,
social support, cognition, communication and bodily discom-
fort. Lower scores indicate better perceived health status
(0 = perfect health, 100 = worst health). PDQ-39 is validated
in PD and its clinimetrics have been extensively evaluated.
Reliability (evaluated by Cronbach’s a for internal consistency)
is very satisfactory except for social support (0.66) while
construct validity (examined by comparing PDQ-39 scores with
relevant SF-36 scores, Unified Parkinson’s Disease Rating Scale
(UPDRS), HY scale and Columbia Rating Scale) shows
significant correlation between the scales.6 9 There is sensitivity
to change, suggesting that PDQ-39 can be used to evaluate
treatment.10 Higher order factor analysis was used to derive the
overall single index score, the PDQ-39 summary index (PDQ-
39SI), from the eight dimension scores.9 The PDQ-39SI shows
high levels of internal validity and construct validity.
All patients completed the PDQ-39 themselves. Completion
of the UPDRS11 and other scales and instruments was optional.
At follow-up after 6–12 months, a separate form was used
noting any interventions in the intervening period (drug
treatment started for DNPD or added for MTPD), a clinical
global impression scale for patients and physician, HY stage,
changes in social or other support services or circumstances,
any change in diagnosis (emergence of atypical parkinsonian
features at follow-up), any drug related side effects and the
PDQ-39.
The data in this paper relate specifically to the DNPD patients
recruited to PDLIFE and their serial follow-up over a mean
period of 18 months. Other aspects of this study relating to the
overall database will not be discussed. Ten centres across the
UK contributed during phase 1. The study was registered as a
prospective audit of existing clinical practices, using established
scales in routine use, and specific ethics approval was not
required.
Statistical analysis
Data were analysed using the Statistical Package for the Social
Sciences (SPSS version 13, Chicago, Illinois, USA). For
statistical analysis of the overall mean single index score
(PDQ-39SI) a two way mixed ANOVA (treatment type as the
between factor and time period as the within factor) was used.
Further comparisons were made where appropriate. Mean
separate PDQ-39 domains were analysed using a three way
mixed ANOVA (treatment type as the between factor, time and
the eight domains of the PDQ-39 as the within factors).
RESULTS
The current report is based on a sample of 198 patients that
were DNPD at the baseline assessment and were followed-up
for mean of 18 months (fig 1). Mean age of the DNPD patients
was 63.4 (9.2) years (range 45–86), 48% were male, mean HY
stage was 1.6 (0.67) (range 1–3) and mean duration of disease
was 4 years (range 0.3–6).
In all, 95% (n = 188) of the 198 DNPD cases returned for
their first follow-up after a mean period of 9 months (range 6–
15) (fig 1). Of these, 60.6% (n = 114) remained untreated
(DNPD group). The remaining 39.4% (n = 74) were started
on anti-PD treatment (monotherapy) after the first consulta-
tion and the initiation treatment varied between levodopa
Baseline
n = 198
Drug-naive
n = 198
(100%)
Monotherapy
n = 0
(0%)
Monotherapy
n = 74
(39%)
Monotherapy
n = 127
(68%)
Monotherapy
n = 74
Monotherapy
n = 53
Drug-naive
n = 114
(61%)
Drug-naive
n = 61
(32%)
Follow-up stage 1
(9 months)
n = 188
(n = 10 lost to follow-up)
Follow-up stage 2
(18 months)
n = 188
Figure 1 Disposition of the 198 initially drug naı¨ve patients with
Parkinson’s disease at follow-up. Of those attending for follow-up, 61%
remained drug naı¨ve at the first follow-up (at a mean of 9 months) and 32%
remained drug naı¨ve at the second follow-up (at a mean of 18 months).
Table 1 Baseline age, Hoehn and Yahr (HY) score,
comorbidity and sociodemographic profiles, according to
whether patients remained drug naı¨ve at the second follow-
up (n = 61) or were started on monotherapy between the
first and second follow-up (n = 53)
Drug naı¨ve Monotherapy
Mean age (y) 66 65
Mean HY score 1.7 1.7
% Male 52 40
% Caucasian 97 93
% Comorbidity
Hypertension 16 16
Diabetes 8 10
Heart disease 12 6
Stroke 4 0
Depression 0 10
HY score, Hoehn and Yahr score.
Depression was significantly higher in the monotherapy group compared
with the drug naı¨ve group (p,0.001, x2) but there were no other significant
differences.
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preparations (51%), dopamine agonists (43%) and others (6%,
selegiline, trihexyphenidyl and amantadine).
Of the 114 subjects that remained untreated at the first
follow-up, 61 (53.5% of 114) remained untreated at the second
follow-up, a mean period of 18 months (range 15–20) following
the baseline consultation. Demographic details of the DNPD
and MTPD patients at the second follow-up are shown in
table 1. Age, HY score, comorbidity and sociodemographic
profile were similar between the DNPD patients who were not
started on treatment compared with those who were, except for
the rate of depression (as noted by a question in the audit form)
which was significantly higher in the treated group (0% vs 10%;
p,0.001). At follow-up, HY scores did not change significantly
in either group although there was a trend towards increasing
HY scores in both groups.
In patients who returned for review and remained drug naı¨ve
(DNPD), there was a progressive deterioration in PDQ-39SI
scores at the first follow-up (p,0.05) with further significant
deterioration at the second follow-up (p,0.05) in those who
were left untreated at the first review (n = 61) (fig 2).
Deterioration was also significant in all eight domains of the
PDQ-39 (fig 3), with PDQ-39 scores worsening significantly at
the second follow-up (p,0.01). The effect size for each
dimension varied between 0.5 and 1.9 at the first follow-up
(for PDQ-39 an effect size of 0.2 is considered small, 0.5 is
moderate and 0.8 is large) and between 0.2 and 0.8 at the
second follow-up.12 The largest effect size was noted for social
stigma (21.98) in those left untreated at the first follow-up. In
contrast, patients initially drug naı¨ve at baseline and started on
treatment between the first and second follow-up visits (fig 3)
showed a trend to deterioration in six out of eight domains of
the PDQ-39 between the baseline and the first follow-up which
appeared to be arrested following treatment between the first
and second follow-up points in which there was a trend
towards improvement (n = 53, p.0.05). Calculation of degree
of change in the individual domains of the PDQ-39 by
measurement of effect size showed small changes towards
improvement in the following domains: activities of daily living
(0.2), social support (0.2), cognition (0.13), communication
(0.1) and bodily discomfort (0.2).
DISCUSSION
We believe that this is the first report of an observational study
of the early stages of PD in patients left untreated at diagnosis,
which focuses on overall self reported health status measures
rather than on motor disability. Self reported health status
measures in PD have also been referred to as measurement of
quality of life although this remains controversial. Although the
mean age of our patients was similar to that in clinical trials, a
greater proportion of older patients (aged up to 86 years) was
studied, as reflected by the greater standard deviation. The
Figure 2 Mean (95% CI) Parkinson’s Disease Questionnaire (PDQ)-39
Summary Index scores in patients initially drug naı¨ve at baseline but who
received anti-PD drug treatment between the first and second follow-up
consultation (n = 53). There was a trend towards worsening between
baseline and the first follow-up (mixed ANOVA, p.0.05) and thereafter a
trend to improvement. For patients who remained drug naı¨ve throughout
the follow-up period (n = 61), the PDQ-39 Summary Index deteriorated
significantly at each visit (overall difference between groups p,0.01,
mixed ANOVA). The horizontal line within the box represents the median
value, with the edges of the box representing the lower and upper quartiles;
the whiskers display the range.
Figure 3 Mean (95% CI) individual dimensions of the Parkinson’s Disease
Questionnaire (PDQ)-39 for patients that remained drug naı¨ve throughout
the follow-up consultations (n = 61) (A). *p,0.01 (mixed ANOVA)
between baseline and the second follow-up in all dimensions. In patients
initially drug naı¨ve at baseline but who received anti-PD drug treatment
between the first and second follow-up consultation (n = 53) (B), there was a
trend to worsening between baseline and the first follow-up in six of the
eight dimensions (mixed ANOVA, p.0.05) and thereafter a trend to
improvement in six of the eight dimensions (B). ADL, activities of daily
living.
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study was based on the PDQ-39 questionnaire, whose domains
include aspects which cover motor (mobility, activities of daily
living) and non-motor (cognition, emotional well being and
bodily discomfort) features of PD. The key finding is that there
was a significant deterioration in all eight domains of the PDQ-
39 scale in those patients who were left untreated at the first
presentation or at the first review. This pattern worsened if
patients did not start treatment at the first review with further
deterioration of quality of life scores at the second review. This
contrasts with untreated PD patients who were given specific
anti-PD treatment at the first review. In these patients, the
PDQ-39 scores remained stable and showed a trend towards
improved quality of life scores in six out of the eight domains of
the PDQ-39 at the second follow-up, suggesting a beneficial
effect of dopaminergic treatment on aspects of the PDQ-39
scale domains, ranging from mobility to bodily discomfort
(fig 3). The observation was supported by the measurement of
effect sizes for each domain which showed a moderate to large
effect size for each domain of the PDQ-39 at the first follow-up
in those left untreated at baseline.
As this was an observational, prospective, audit based study,
we did not influence decisions on when to begin treatment or
drug choice. However, the baseline assessment data allowed us
to compare if there were any major variables that might have
influenced initiation of treatment by the physician in the MTPD
group and not in the DNPD group. As indicated in table 1, a
significantly higher (p,0.001) rate of self declared depression
in MTPD (0% DNPD vs 10% MTPD) was noted before treatment
was started. We assume, therefore, that in these cases the
decision to treat could have been based on the clinician’s
discretion and patient choice and perhaps not functional
disability. A divergent trend between self reported health status
and motor scores/functional disability has also been noted by
the US Parkinson Study Group who made similar observations
relating to self reported health status in their CALM-PD trial
which was a randomised comparison of initial levodopa versus
initial pramipexole.13 In the CALM-PD study, although the
motor scores improved more with levodopa, the self reported
health status scores, as measured by the PDQUALIF14 scale,
were similar between levodopa and pramipexole.
There are obvious drawbacks of audit or clinical practice-led
observational studies such as this which merit discussion.
Firstly, the longitudinal follow-up of the 198 DNPD patients
was not complete, with 188 returning for follow-up visits to
date in this ongoing work, but does reflect a high retention rate
at follow-up. Secondly, the numbers of patients remaining drug
naı¨ve at the second follow-up were low. In spite of this, there
was a robust deterioration in the self reported health status
scores, both overall and within individual domains of the PDQ-
39, suggesting the severity of this problem if patients are left
untreated. Data on patients treated at baseline and followed up
thereafter (n = 74) will be reported later as part of the overall
study. Thirdly, this was an observational and not a randomised
study of the effect of treatment of anti-PD drugs, such that only
limited conclusions can be reached about the relative merits of
levodopa versus dopamine agonist treatment. These issues are
more appropriately addressed by randomised studies such as
the large national pragmatic trial in the UK comparing the use
of various anti-PD agents used to initiate treatment of PD and
their effect on self reported health status using the PDQ-39 as
the primary end point (the PDMED study). Another criticism is
the absence of UPDRS scoring, the ‘‘gold standard’’ for
assessment of PD motor impairment.11 However, a core aim of
the study was to move away from recording of impairment
which may not reflect other determinants of self reported
health status such as non-motor symptoms, and furthermore
the UPDRS is in the process of amendment.15–17
We consider the strengths of the study as the inclusion of
‘‘real life’’ patients with no restriction on age groups or
comorbidities, and the longitudinal analysis of 188 DNPD
cases, the largest reported collection of untreated PD cases over
time focusing on self reported health status measures. While a
PD specific non-motor questionnaire (NMSQuest) and scale
have been validated recently, at the time of the study the PDQ-
39 provided an indirect indicator of non-motor and motor
symptoms of PD.18 19 It is also recognised that the UPDRS may
not predict health related self reported health status, as
exemplified by the comparison of pramipexole and levodopa
as initial treatment for drug naı¨ve PD.13 Similar results have
also been reported from the pilot validation study of the Unified
Non-motor Symptoms Scale for PD which appears to predict
self reported health status in PD in a more robust fashion than
the UPDRS in a large population of PD patients across all
stages.19 A take home message from this study may be the re-
evaluation of the policy whereby some physicians may elect to
delay treatment in newly diagnosed PD, a topic that had
recently prompted conflicting views.20 21 However, in these
reviews, the argument for starting treatment at diagnosis or
delaying treatment in PD was largely based on motor
disabilities such as dyskinesias, issues related to neuroprotec-
tion and cost of medication, and not what happens to self
reported health status or quality of life if such patients are left
untreated. Studies by the Global PD Steering Committee and
others have indicated that factors other than motor scores
dictate overall quality of life in PD.17 22 Our work would suggest
that self reported health status of PD needs to be an essential
part of this debate.
In conclusion, based on the results of this ‘‘real life’’
observational study of the journey of untreated PD patients, it
appears that in patients presenting to doctors who are then left
untreated, there is a clinically important and possibly reversible
deterioration in all eight domains of the PDQ-39 scale.
Deterioration is observed not only in the motor domains but
also in the non-motor domains, such as cognition, bodily
discomfort, emotional well being and communication. This
contrasts with PD patients in whom treatment is started where
the PDQ-39 scores remain stable and show no deterioration,
regardless of whether they are prescribed levodopa or other
anti-PD treatments. We believe that PD specific measures of self
reported health status should be integral to the clinical
assessment of patients at review and also while evaluating
response to treatment.
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